Richard White

Richard White is a seasoned professional in the biochemistry and pharmaceutical sectors, currently serving as Senior Scientific Advisor and a member of the Board of Directors at F2G, a private antifungal company based in Manchester, UK, since 2006. In addition, Richard has provided scientific advisory services to Cortexyme Inc. and Spero Therapeutics since April 2015 and has been a consultant at Half Moon Bay Biotechnology Consulting since January 2006. Richard holds a pivotal role as Chairman of the Scientific Advisory Board at Cempra Pharmaceuticals Inc. and has previously served in various advisory and board positions at companies including INDEL, Trius Pharmaceuticals, and Biorelix. Educational credentials include a D Phil in Biochemistry from the University of Oxford and a BSc&Tech in Biochemistry from The University of Manchester.